Kalyan Jewellers Share Price In Focus As 5 Crore Block Deal Emerges
Key Takeaways
- A prominent domestic mutual fund may offload about 5 crore Kalyan Jewellers shares.
- The sale could occur outside the block window and at an 8%-10% discount to the current market price.
- The seller is expected to remain a shareholder after the deal.
- Markets will stay focused on the Kalyan Jewellers share price amid the development.
What happens when a 5 crore share block sale lands outside the exchange window, and the price is expected to be an 8%-10% discount to the current kalyan jewellers share price? For retail investors tracking Kalyan Jewellers share price, this isn't just a single trade–it is a significant liquidity event that could shape near-term sentiment and price discovery for the stock.
Kalyan Jewellers Share Price: Block Deal Size And Pricing
According to people familiar with the matter, the block deal involves about 5 crore shares. The seller is a prominent domestic mutual fund. Two bankers have been appointed to manage the proposed deal. The sale would occur outside the exchange-designated block deal window and could take place at any time, making the timing uncertain. The pricing expectation is an 8%-10% discount to the current market price. If completed, the deal would keep the mutual fund as a shareholder post-transaction.
The immediate market implication hinges on how this new supply interacts with existing liquidity. With such a large size, the block could tilt the intraday supply-demand dynamic and influence the kalyan jewellers stock price in the near term. Traders will likely watch for how the order book absorbs the 5 crore-share block and whether the price retraces to the pre-deal levels or overshoots on supply absorption. The discount is designed to attract buyers and aid swift execution, but it also signals potential volatility around the transaction window.
For readers seeking deeper, AI-driven analysis of stock moves like this, consider Swastika's Sarthi AI stock assistant: Swastika's Sarthi AI stock assistant.
Who Is Selling In The Kalyan Jewellers Block Deal And What It Means For Market Demand
The seller is a prominent domestic mutual fund, indicating a strategic portfolio rebalancing rather than a sweeping exit. In this setup, the fund may reduce its holding but is expected to remain a shareholder afterward, suggesting a partial rollover rather than liquidation. For investors, this means the block could create a brief liquidity event but might not alter the long-term ownership narrative. The stock's price action will also depend on how the market interprets the motive behind the sale and whether other buyers step in to absorb the supply near the discount zone.
From a trading perspective, the Kalyan Jewellers share price near the discount range could find intraday support if buyers participate at the indicated price, or it could slip if the market is cautious about the overall liquidity environment. The transaction's scale–5 crore shares–could be material relative to typical daily trading volumes for Kalyan Jewellers Ltd., and that relative size makes liquidity watching essential for retail investors. This is one more reminder that a single block deal can reframe sentiment, at least in the short run.
Timing, Window, And The 8% To 10% Discount On The Kalyan Jewellers Block Deal
The sale is outside the exchange-designated block deal window, so timing remains flexible and could occur at any time. While such a window exists to maintain orderly trading, this deal's outside-window nature means the market may not anticipate the exact moment of execution. The discount range of 8%-10% to the current market price is a critical feature: it acts as an incentive to attract participants and affects the price discovery process. Two bankers have been appointed to manage the deal, providing a structured pathway for price formation and regulatory compliance.
Retail investors should watch how the Kalyan Jewellers share price behaves around the deal's execution, particularly if the price gaps between the pre-deal quotes and the executing price widen. If the market perceives the discount as a sign of strong demand, the share price could rebound quickly; if not, the stock could endure a more drawn-out adjustment. Remember that block deals are not standalone catalysts; they shift the supply dynamics and interact with broader market conditions.
Post-Deal Outlook: The Mutual Fund's Steady Hand And The Potential For The Kalyan Jewellers Share Price
After the block deal, the mutual fund is expected to remain a shareholder. This outcome implies the move is more about rebalancing than a complete disposal of the holder's stake. The 5 crore share block deal could continue to influence liquidity and sentiment around Kalyan Jewellers stock price in the near term. Investors should monitor the kalyan jewellers stock price to gauge how quickly price discovery finds a new equilibrium and whether any follow-up moves emerge as traders digest the deal's implications.
Related Reads
Frequently Asked Questions
What Is The Size Of The Proposed Block Deal In Kalyan Jewellers?
About 5 crore shares.
Who Is Selling In The Kalyan Jewellers Block Deal?
A prominent domestic mutual fund.
What Is The Expected Discount To The Current Market Price?
8% to 10% discount.
Will The Mutual Fund Exit Its Stake After The Block Deal?
No. The fund is expected to remain a shareholder post-transaction.
When Could The Block Deal Take Place?
Outside the exchange-designated block deal window and could occur at any time.
Who Are The Deal Managers For This Block Deal?
Two bankers have been appointed to manage the proposed deal.
Conclusion
The 5 crore block deal highlights how liquidity events can shape near-term price action for Kalyan Jewellers share price, even when the seller remains a shareholder after the deal. Retail investors should use the price action around the block to calibrate risk and potential entry points, while avoiding over-interpretation of a one-off event. As always, pair price actions with fundamental context and a disciplined exit plan to navigate volatility and preserve capital.
Open your trading and demat account here
Reference :
1 : Ndtvprofit
Latest Articles
Kalyan Jewellers Share Price In Focus As 5 Crore Block Deal Emerges
Key Takeaways
- A prominent domestic mutual fund may offload about 5 crore Kalyan Jewellers shares.
- The sale could occur outside the block window and at an 8%-10% discount to the current market price.
- The seller is expected to remain a shareholder after the deal.
- Markets will stay focused on the Kalyan Jewellers share price amid the development.
What happens when a 5 crore share block sale lands outside the exchange window, and the price is expected to be an 8%-10% discount to the current kalyan jewellers share price? For retail investors tracking Kalyan Jewellers share price, this isn't just a single trade–it is a significant liquidity event that could shape near-term sentiment and price discovery for the stock.
Kalyan Jewellers Share Price: Block Deal Size And Pricing
According to people familiar with the matter, the block deal involves about 5 crore shares. The seller is a prominent domestic mutual fund. Two bankers have been appointed to manage the proposed deal. The sale would occur outside the exchange-designated block deal window and could take place at any time, making the timing uncertain. The pricing expectation is an 8%-10% discount to the current market price. If completed, the deal would keep the mutual fund as a shareholder post-transaction.
The immediate market implication hinges on how this new supply interacts with existing liquidity. With such a large size, the block could tilt the intraday supply-demand dynamic and influence the kalyan jewellers stock price in the near term. Traders will likely watch for how the order book absorbs the 5 crore-share block and whether the price retraces to the pre-deal levels or overshoots on supply absorption. The discount is designed to attract buyers and aid swift execution, but it also signals potential volatility around the transaction window.
For readers seeking deeper, AI-driven analysis of stock moves like this, consider Swastika's Sarthi AI stock assistant: Swastika's Sarthi AI stock assistant.
Who Is Selling In The Kalyan Jewellers Block Deal And What It Means For Market Demand
The seller is a prominent domestic mutual fund, indicating a strategic portfolio rebalancing rather than a sweeping exit. In this setup, the fund may reduce its holding but is expected to remain a shareholder afterward, suggesting a partial rollover rather than liquidation. For investors, this means the block could create a brief liquidity event but might not alter the long-term ownership narrative. The stock's price action will also depend on how the market interprets the motive behind the sale and whether other buyers step in to absorb the supply near the discount zone.
From a trading perspective, the Kalyan Jewellers share price near the discount range could find intraday support if buyers participate at the indicated price, or it could slip if the market is cautious about the overall liquidity environment. The transaction's scale–5 crore shares–could be material relative to typical daily trading volumes for Kalyan Jewellers Ltd., and that relative size makes liquidity watching essential for retail investors. This is one more reminder that a single block deal can reframe sentiment, at least in the short run.
Timing, Window, And The 8% To 10% Discount On The Kalyan Jewellers Block Deal
The sale is outside the exchange-designated block deal window, so timing remains flexible and could occur at any time. While such a window exists to maintain orderly trading, this deal's outside-window nature means the market may not anticipate the exact moment of execution. The discount range of 8%-10% to the current market price is a critical feature: it acts as an incentive to attract participants and affects the price discovery process. Two bankers have been appointed to manage the deal, providing a structured pathway for price formation and regulatory compliance.
Retail investors should watch how the Kalyan Jewellers share price behaves around the deal's execution, particularly if the price gaps between the pre-deal quotes and the executing price widen. If the market perceives the discount as a sign of strong demand, the share price could rebound quickly; if not, the stock could endure a more drawn-out adjustment. Remember that block deals are not standalone catalysts; they shift the supply dynamics and interact with broader market conditions.
Post-Deal Outlook: The Mutual Fund's Steady Hand And The Potential For The Kalyan Jewellers Share Price
After the block deal, the mutual fund is expected to remain a shareholder. This outcome implies the move is more about rebalancing than a complete disposal of the holder's stake. The 5 crore share block deal could continue to influence liquidity and sentiment around Kalyan Jewellers stock price in the near term. Investors should monitor the kalyan jewellers stock price to gauge how quickly price discovery finds a new equilibrium and whether any follow-up moves emerge as traders digest the deal's implications.
Related Reads
Frequently Asked Questions
What Is The Size Of The Proposed Block Deal In Kalyan Jewellers?
About 5 crore shares.
Who Is Selling In The Kalyan Jewellers Block Deal?
A prominent domestic mutual fund.
What Is The Expected Discount To The Current Market Price?
8% to 10% discount.
Will The Mutual Fund Exit Its Stake After The Block Deal?
No. The fund is expected to remain a shareholder post-transaction.
When Could The Block Deal Take Place?
Outside the exchange-designated block deal window and could occur at any time.
Who Are The Deal Managers For This Block Deal?
Two bankers have been appointed to manage the proposed deal.
Conclusion
The 5 crore block deal highlights how liquidity events can shape near-term price action for Kalyan Jewellers share price, even when the seller remains a shareholder after the deal. Retail investors should use the price action around the block to calibrate risk and potential entry points, while avoiding over-interpretation of a one-off event. As always, pair price actions with fundamental context and a disciplined exit plan to navigate volatility and preserve capital.
Open your trading and demat account here
Reference :
1 : Ndtvprofit
Laurus Labs Share Price Rally: Q1FY27 Profit Jump And Growth Drivers
Key Takeaways
- Laurus Labs share price rose 4.05% to Rs 1,666 in Monday’s session.
- Q1FY27 net profit jumped 126% YoY to Rs 368 crore on revenue of Rs 2,026 crore.
- EBITDA margin expanded to 31.8%, up 7 percentage points year over year.
- FII stake rose to 28% in the June quarter; the stock has gained about 45% in 3 months and about 92% in 1 year.
Laurus Labs share price rose on Monday as investors digested Laurus Labs’ Q1FY27 numbers, which showed a net profit up 126% year-on-year to Rs 368 crore on revenue of Rs 2,026 crore. The quarter also delivered EBITDA of Rs 644 crore and an EBITDA margin of 31.8%, up seven percentage points from a year ago. Gross margins climbed to 62.7%, buoyed by efficient cost management and stronger CDMO deliveries, while capex during the quarter was 19% of sales. With FY27 and FY28 expansion plans on track, the directional bias remains constructive for the stock.
According to Dr Satyanarayana Chava of Laurus Labs, We delivered record quarterly revenue along with improved profitability, driven by increasing commercial deliveries in CDMO and sustained performance in affordable medicines, with EBITDA margin at 31.8% and gross margin at 62.7%.
Reference :
1 : Economictimes
Laurus Labs Share Price Rally After Q1FY27 Profit Jump
The stock rose 4.05% to Rs 1,666 in Monday’s trading session, reflecting a robust reaction to the quarter’s numbers. Q1FY27 net profit rose 126% YoY to Rs 368 crore on revenue of Rs 2,026 crore, underscoring a strong top-line performance alongside margin improvements. The momentum is part of a broader uptrend with approximately 45% gains in the last three months and roughly 92% gains over the last year. Management attributed the earnings improvement to higher CDMO commercial deliveries and continued strength in the affordable medicines segment. EBITDA for the quarter stood at Rs 644 crore, with the EBITDA margin at 31.8% and gross margins at 62.7%, aided by disciplined cost control and favorable product mix. The company also highlighted capex discipline (19% of sales) and an on-track expansion roadmap for FY27 and FY28.
Laurus Labs Quarterly Results And Q1FY27 Highlights
From the quarterly disclosures, revenue from operations reached Rs 2,026 crore in Q1FY27, up from Rs 1,570 crore in Q1FY26. Net profit printed at Rs 368 crore, a 126% YoY jump, while EBITDA rose to Rs 644 crore. EBITDA margin expanded to 31.8%, and gross margins stood at 62.7%. Capex during the quarter was 19% of sales. FII stake rose from 25.82% to 28% in the June 2026 quarter, reflecting stronger institutional confidence. Management reiterated that the capex plans for FY27 and FY28 remain on schedule, with CDMO and affordable medicines continuing to be growth engines for the year ahead.
Laurus Labs CDMO Growth: The Primary Growth Driver
The key growth driver in Q1FY27 was the uptick in commercial CDMO projects, which supported higher revenue and helped sustain profitability. CDMO growth translated into expanding margins and a stronger top line as the company reinforced its manufacturing and development capabilities to capture higher-value contracts. In addition, Laurus Labs is entering into agreements to in-license two antibody-drug conjugates, a strategic step to broaden its late-stage pipeline. The final handover of a new land parcel is expected to support future expansion capacity for FY27 and FY28, reinforcing the company’s long-term growth trajectory.
Laurus Labs Stock Price Momentum: RSI And Moving Averages
Technically, the setup remains supportive. The 14-day RSI sits at 66.3, suggesting room for upside before hitting overbought territory. The stock is trading above all eight key SMAs, indicating a broad-based positive trend across short- and mid-term horizons. This favorable technical posture aligns with the fundamental strength seen in Q1FY27, particularly the CDMO-driven growth and the steady performance in affordable medicines. Traders should monitor continued momentum in CDMO project wins and any updates related to ADC licensing deals and capex execution. For deeper, institution-level stock research, consider Swastika's Sarthi AI stock assistant.
Expansion Plans And Future Growth Outlook: Capex And In-License Deals
Capex during Q1FY27 was 19% of sales, and Laurus Labs reiterates that its capex plan for FY27 and FY28 remains on schedule. The company is also entering into agreements to in-license two antibody-drug conjugates, expanding its late-stage pipeline and potential pricing power. The final land parcel handover will support expansion capacity and new product lines in the coming years. This expansion, combined with CDMO growth and sustained demand for affordable medicines, strengthens the growth narrative while requiring ongoing attention to cash flow generation and debt management as the year unfolds.
Investment Profile: FII Stance, Market Cap And What It Means For Investors
FII participation rose to 28% in the June 2026 quarter from 25.82%, signaling continued institutional interest. The market capitalization stood at approximately Rs 86,505 crore, reflecting the market’s assignment of a strong growth premium to Laurus Labs’ CDMO and affordable medicines franchise. The combination of a constructive technical setup (RSI and moving averages) with solid revenue growth and margin expansion supports a favorable view for investors with a longer horizon, while acknowledging the volatility typical of pharma outsourcing cycles. Investors should align this with their risk tolerance and investment goals.
Frequently Asked Questions
What were Laurus Labs Q1FY27 revenue and net profit?
Revenue from operations was Rs 2,026 crore in Q1FY27, up from Rs 1,570 crore in Q1FY26. Net profit rose 126% YoY to Rs 368 crore.
What drove Laurus Labs' strong Q1FY27 performance?
Growth drivers included increased commercial projects in the CDMO segment and sustained momentum in the affordable medicines portfolio.
What is Laurus Labs' stock price momentum and technical picture after Q1FY27?
The stock gained about 4.05% to Rs 1,666 in the session following the results. The 14-day RSI stood at 66.3, and the stock traded above all eight key SMAs.
What expansion plans did Laurus Labs announce for FY27 and FY28?
Capex during the quarter was 19% of sales, and management stated that capex plans for FY27 and FY28 remain on schedule. The company is in-licensing two antibody-drug conjugates and completed the handover of a new land parcel to support expansion.
What is the market backdrop for Laurus Labs as of the June 2026 quarter?
FII stake rose to 28% in the June 2026 quarter, and the market capitalization was about Rs 86,505 crore, reflecting strong investor interest in Laurus Labs' CDMO and affordable medicines franchises.
Conclusion
From a retail-investor standpoint, the Q1FY27 results reinforce Laurus Labs as a CDMO-led growth play with improving profitability and a disciplined capex trajectory. The momentum in CDMO projects, the licensing of two antibody-drug conjugates, and the completion of expansion-capacity investments position the company well to monetize higher-value contracts in the years ahead. While valuations may reflect the growth premium, the combination of robust top-line growth, expanding margins, and a constructive technical backdrop provides a compelling setup for investors who can tolerate near-term volatility tied to macro and regulatory dynamics.
Zen Technologies Share Price: Q1FY27 Results, Rs 1,239 Crore Order Book, And Outlook
Key Takeaways
- Zen Technologies share price fell 6.43% to Rs 1,655 after Q1FY27 results showed profit decline of 27.8% YoY and revenue decline of 10.5%.
- The company closed Q1FY27 with an order book of Rs 1,239.02 crore as of June 30, 2026, and received a Rs 177.50 crore simulator order in July 2026.
- Most executable orders are expected to translate into revenue from Q2FY27 onwards, with a typical 12-month execution cycle for visibility.
- The stock is trading below several key SMAs and RSI sits at 47, with FIIs and MF holdings rising in the latest quarter.
Zen Technologies Share Price: Q1FY27 Results And The Road Ahead
Zen Technologies share price moved in response to Q1FY27 results, where consolidated net profit fell 27.8% year-on-year to Rs 34 crore and revenue declined 10.5% to Rs 141.6 crore. The stock dropped 6.43% to Rs 1,655 in Monday's session as investors weighed near-term execution against a robust order book. The zen technologies order book stood at Rs 1,239.02 crore as of June 30, 2026, while a simulator order worth Rs 177.50 crore was received in July 2026, adding a near-term revenue trigger.
The majority of the executable order book is expected to translate into revenue from Q2FY27 onwards, with most orders secured from October 2025 onwards. These orders typically have an execution cycle of around 12 months, providing visibility for revenue conversion over the next several quarters.
Key data points at a glance show how the quarter progressed: consolidated net profit Rs 34 crore versus Rs 47 crore a year ago; revenue Rs 141.6 crore versus Rs 158.2 crore. The stock's market capitalization hovers around Rs 15,970 crore, with the 52-week high at Rs 2,024. The stock's 14-day RSI sits at 47, and it is trading below five out of eight key SMAs, including the 100-day, 150-day, and 200-day SMAs. FII stake rose to 6.47% and mutual fund holdings rose to 7.55% in the quarter.
Investors can monitor the trajectory of the order book to revenue conversion in the coming quarters, as Q2FY27 delivery schedules progress. For deeper, independent stock research, you can explore Swastika's Sarthi AI stock assistant.
Zen Technologies Order Book: What Rs 1,239.02 Crore Means For Revenue
As of June 30, 2026, the company reported a consolidated order book of Rs 1,239.02 crore. That order book is the backbone of revenue visibility for the next several quarters, especially given the typical 12-month execution cycle for orders in this sector. The Rs 1,239.02 crore order book is paired with a Rs 177.50 crore simulator order received in July 2026, which is expected to contribute to revenue in the near term.
Management has indicated that a majority of executable orders are expected to translate into revenue starting from Q2FY27 onwards, aligning delivery schedules with revenue realization. The pipeline, largely secured from October 2025 onwards, provides a multi-quarter horizon for revenue conversion, even as Q1FY27 results showed pressure on profits and revenue.
Zen Technologies Quarterly Results: Parsing The Q1FY27 Performance And Q2FY27 Outlook
Q1FY27 consolidated net profit of Rs 34 crore marks a 27.8% decline from Rs 47 crore in the prior year period. Revenue from operations came in at Rs 141.6 crore, down 10.5% YoY from Rs 158.2 crore. Despite this, the order book remains above the Rs 1,000 crore mark, and most of it has a delivery schedule aligned for revenue realization in the subsequent quarters.
Q2FY27 outlook remains anchored by the bulk of orders executed in the next 12 months. The near-term revenue visibility is shaped by a strong order intake from late 2025, with an execution cycle of roughly one year, offering a path to revenue normalization as we move deeper into FY27.
From Order Book To Revenue: The 12-Month Execution Cycle And Visibility
The execution cycle for orders in Zen Technologies is typically around 12 months, which means the majority of the executable order book translates into revenue over the next several quarters. The July 2026 simulator order adds to near-term revenue visibility, while the base order book provides longer-term demand coverage. Investors should track the pace of delivery and the conversion of order book into revenue as Q2FY27 unfolds.
Technical Snapshot For Zen Technologies Share Price: RSI, Moving Averages, And Price Action
The stock's 14-day RSI stands at 47, suggesting a neutral near-term momentum. The price action shows the stock trading below five out of eight key SMAs, including the 100-day, 150-day, and 200-day SMAs, indicating potential resistance ahead if the price fails to reclaim these average levels. The stock has gained about 3% over the past three months, reflecting a modest recovery amid the broader market volatility. The 52-week high is Rs 2,024, underscoring the headroom for upside if fundamentals improve and new revenue streams materialize.
Ownership And Market Sentiment: FII And MF Stakes And The Price Action
Foreign institutional investors (FIIs) increased their stake from 5.99% to 6.47% in the quarter, while mutual fund holdings rose from 6.72% to 7.55%. The stock's price action indicates volatility around the Q1FY27 results, with a 6.43% daily drop to Rs 1,655 in one session but a cumulative gain of around 3% over the prior three months. Market capitalization stands near Rs 15,970 crore, reflecting the market's expectation of revenue conversion from a robust order pipeline over the next 12 months.
For retail investors, Swastika's Sarthi AI stock assistant can be a useful, institution-level research companion. Learn more here: Swastika's Sarthi AI stock assistant.
Frequently Asked Questions
What was Zen Technologies' consolidated net profit in Q1FY27?
Rs 34 crore, a 27.8% year-on-year decline from Rs 47 crore in the same period last year.
What was the revenue from operations in Q1FY27?
Rs 141.6 crore, down 10.5% year-on-year from Rs 158.2 crore.
What is the Zen Technologies order book as of June 30, 2026?
Rs 1,239.02 crore consolidated order book.
What is the Rs 177.50 crore simulator order and when was it received?
It is a simulator order worth Rs 177.50 crore received in July 2026.
How did Zen Technologies' stock price react after Q1FY27 results?
Shares fell 6.43% to Rs 1,655 in the corresponding trading session.
What were the FII and MF stake movements in the quarter?
FII stake rose to 6.47% from 5.99%; MF holdings rose to 7.55% from 6.72%.
Conclusion
The Zen Technologies share price narrative is a study in the interplay between near-term profitability and longer-term revenue visibility. While Q1FY27 profits fell and revenue declined, the Rs 1,239.02 crore order book and a Rs 177.50 crore simulator order signal that the execution engine is still intact. Retail investors should focus on revenue conversion in the coming quarters and track delivery schedules against the order book to gauge the trajectory of Zen Technologies share price over FY27.
Open your trading and demat account here
Reference :
1 : Economictimes
Manipal Health Enterprises IPO: A Retail Investor's Comprehensive Guide To The Rs 9,275 Crore Public Offering
Key Takeaways
- Manipal Health Enterprises IPO is a Rs 9,275 crore healthcare offering with a price band of Rs 560-590 per share.
- Fresh issue comprises 13.56 crore shares aggregating to Rs 8,000 crore, plus an OFS of 2.16 crore shares.
- Estimated listing price is Rs 615 per share, implying a listing gain of about 4.24%.
- Retail investors must bid for at least one lot of 25 shares, equating to Rs 14,750 at the upper price.
Manipal Health Enterprises IPO stands out as one of the year’s most anticipated healthcare public offerings. Valued at Rs 9,275 crore, the deal opens for subscription from July 29 to July 31, 2026, with allotment on August 3 and listing on August 5 on both the NSE and the BSE. The GMP data as of July 27, 2026 shows Rs 25, hinting at a modest listing premium of around 4% under the current pricing framework. Retail investors can bid in lots of 25 shares at a price band of Rs 560-590 per share, implying a minimum investment of Rs 14,750 at the upper price. This article consolidates the issuer’s data into a practical framework to help you decide whether this healthcare IPO belongs in your portfolio.
To navigate this opportunity, it’s essential to understand the IPO’s structure, the timing, and the potential upside or risk scenarios that can unfold on listing. The Manipal Health Enterprises IPO is a book-built issue that includes a fresh issue and an offer for sale (OFS). The lead manager is Kotak Mahindra Capital Co. Ltd., and the registrar is Kfin Technologies Ltd. The issuer behind this offering, Manipal Health Enterprises Ltd., is incorporated in 2010 and operates a large network of multi-specialty hospitals, clinics, and diagnostic centres across India. The objective behind the fund-raise is twofold: to repay outstanding borrowings of its subsidiary, Manipal Hospitals Private Ltd., and to pursue strategic minority investments–such as a minority stake in Sahyadri Hospitals Private Limited–along with meeting general corporate purposes. Investors should read the red herring prospectus carefully to understand all risks and use-of-proceeds in detail.
Manipal Health Enterprises IPO: Breaking Down The Rs 9,275 Crore Public Offer
The offer comprises a fresh issue and an OFS, with the total size pegged at Rs 9,275 crore. Specifically, the fresh issue consists of 13.56 crore shares aggregating to Rs 8,000 crore, while the OFS comprises 2.16 crore shares. This structure balances primary capital infusion with secondary market liquidity for existing shareholders. Kotak Mahindra Capital Co. Ltd. leads the book execution, and Kfin Technologies Ltd. serves as the registrar. Incorporated in 2010, the company operates a widespread network of hospitals, clinics, and diagnostic centres. The IPO aims to fund expansion plans, debt reduction in the group’s subsidiaries, and selective acquisitions within the hospital ecosystem, including Sahyadri Hospitals Private Limited, to strengthen regional footprints.
Retail participation stands out in this offer with a minimum bid of one lot of 25 shares. The lot size is 25 shares, and the price band is Rs 560-590 per share, translating to a minimum investment of Rs 14,000 at the lower band or Rs 14,750 at the upper band. The lead managers and the registrar have laid out a transparent framework to process bids and allocate shares, with allocation likely to be on a proportionate or hybrid basis depending on demand. The public mechanism is designed to channel capital into hospital network expansion while offering liquidity opportunities to existing promoters and shareholders.
For quick reference, here is a snapshot of the core IPO metrics (values are as disclosed in the offer document):
| Parameter | Value |
|---|---|
| IPO Size | Rs 9,275 crore |
| Fresh Issue | 13.56 crore shares, Rs 8,000 crore |
| OFS | 2.16 crore shares |
| Price Band | Rs 560-590 |
| Upper Price | Rs 590 |
| Estimated Listing Price | Rs 615 |
| Estimated Listing Gain | 4.24% |
| GMP (as of July 27, 2026) | Rs 25 |
| Retail Lot Size | 25 shares |
| Retail Minimum Bid | One Lot |
| Open Date | July 29, 2026 |
| Close Date | July 31, 2026 |
| Allotment Date | August 3, 2026 |
| Listing Date | August 5, 2026 |
| Lead Manager | Kotak Mahindra Capital Co. Ltd |
| Registrar | Kfin Technologies Ltd |
The pricing math includes the cap price plus today’s GMP to estimate a listing price. With a cap price of Rs 590 and a GMP of Rs 25, the model yields an estimated listing price of Rs 615. However, it’s crucial to remember that GMP is dynamic and speculative; the actual listing price on the first day will depend on investor demand, market conditions, and supply dynamics. This framework provides a directional sense of potential upside rather than a binding forecast.
The corporate purpose behind the proceeds includes debt repayment for the subsidiary, the strategic acquisition of minority holdings like Sahyadri Hospitals Private Limited, and general corporate purposes. These uses signal an intent to strengthen balance sheets and accelerate growth in a sector where capacity constraints often determine revenue trajectories. For investors, the key question is whether the growth in revenue (and EBITDA) can outpace the increased equity base and any integration risks that accompany rapid expansion.
Pricing And Valuation: The Price Band, GMP And The Est Listing Price
The price band of Rs 560-590 per share places the Manipal Health Enterprises IPO within a mid-to-upper range for hospital networks of its scale. The upper price target of Rs 590 acts as the anchor for retail investors evaluating the upfront capital outlay. With a GMP of Rs 25 as of July 27, 2026, the market is signaling a potential listing price near Rs 615 per share when combined with the cap price. This suggests an estimated listing gain of about 4.24% based on the cap price plus GMP calculation. Investors should treat this as a rough directional guide rather than a guarantee, given that GMP is a speculative benchmark that can swing in the days leading up to listing.
From a performance perspective, the company reported FY26 total income of Rs 10,520.52 crore, up from Rs 8,362.79 crore in FY25, signaling a YoY growth of 26%. EBITDA for FY26 stood at Rs 2,795.94 crore, versus Rs 2,247.07 crore in FY25. PAT for FY26 was Rs 916.52 crore, down from Rs 1,081.67 crore in FY25. These numbers underscore a core revenue growth story but also highlight the margin pressures that accompany large-scale hospital expansions and integration costs. Investors should weigh whether the growth in top-line translates into sustainable profitability given interest costs and depreciation in a capital-intensive asset class.
Additionally, the source of funding and use of proceeds are critical to the investment thesis. The fresh issue will provide primary capital to the business, while the OFS supports liquidity and governance transitions for existing shareholders. The presence of a prominent sponsor or promoter group plus a credible lead manager can help with mid-cap and large-cap placement, but friction can arise if demand is uneven across investor segments. Keep an eye on the competitive landscape in Indian hospital networks, including regional expansion plans and regulatory movements, which can materially impact valuations on listing day and beyond.
Use Of Proceeds And Growth Prospects: What The IPO Means For The Hospital Network
The net inflow from the fresh issue (Rs 8,000 crore) primarily targets debt repayment for a subsidiary and potential minority stake acquisitions in regional hospital networks, including Sahyadri Hospitals Private Limited. This capital reinforcement can support expansion plans, including new facility rollouts or upgrading existing clinics, diagnostic centres, and specialty units. From a growth perspective, the hospital chain sector benefits from rising healthcare penetration, increased discretionary spend on health, and a broader private-pay mix in India. If the company executes its expansion and integration strategy prudently, the revenue trajectory could sustain higher asset utilization across the network.
Nevertheless, investors must monitor leverage dynamics, as debt repayment interacts with ongoing capex needs. The company’s FY26 EBITDA growth contrasts with a softer PAT print versus FY25, suggesting that higher depreciation and interest costs, plus integration expenses, may dampen profitability in the near term even as revenue expands. A key question for investors is whether the long-run earnings ability and cash flow generation can offset the equity dilution from the fresh issue and the challenges of consolidating a large, diversified healthcare network across multiple geographies.
As a practical investor, you should assess the risk-reward balance by mapping your portfolio’s exposure to healthcare services, asset-heavy businesses, and the regulatory environment. For deeper, stock-level modeling and scenario planning, consider using Swastika’s Swastika's Sarthi AI stock assistant, which can help simulate outcomes under different demand scenarios and cost structures.
Retail Participation, Lot Size And Minimum Investment: A Simple Guide
The retail bid is allowed in lots of 25 shares, with the minimum bid starting at one lot. At the upper end of the price band, a single lot costs Rs 14,750. The lower band would require Rs 14,000 for one lot (25 shares Rs 560). This bifurcation means retail investors can enter the IPO with a relatively modest outlay relative to some other large-cap IPOs, but the price sensitivity remains high given the proximity of the listing price to the upper band. For first-time bidders and casual retail investors, a disciplined approach–such as applying only for a portion of a single lot or using a systematic investment plan style bidding window–can help manage the risk of oversubscription and post-listing volatility.
The fact that the issue is “book-built” and managed by a well-known investment bank adds a layer of credibility to the process, but it also means that market demand will play a primary role in the final allocation and listing performance. Retail investors should prepare bids during the open window (July 29-31, 2026) and be mindful of allotment probabilities, which can be influenced by overall demand as well as retailer vs. institution mix during the auction process.
Risks, Outlook And Takeaways: A Balanced View On The Opportunity
On the risk side, the hospital sector is capital-intensive, heavily regulated, and exposed to reimbursement dynamics and regional competition. The company’s FY26 revenue growth is solid (YoY 26%), but margin expansion hinges on effective cost control and scale benefits as the network expands. The use of proceeds to repay debt is a positive for balance-sheet health, yet the fresh equity will dilute existing earnings per share in the near term until the expansion drives higher volumes and margins. The difference between top-line growth and bottom-line profitability is a critical lens for prospective bidders to apply when evaluating the offer price against future earnings potential.
Investors should compare this IPO with other healthcare and hospital networks to gauge relative valuations. Consider how a diversified network across geographies might cushion regional risks, while also evaluating the impact of regulatory changes on capital expenditure cycles. In practice, a thoughtful approach would combine fundamental metrics (revenue growth, EBITDA, and leverage) with a probabilistic view of listing-day demand, which often drives short-term gains or slippage.
Related Reads
Frequently Asked Questions
What is the size and composition of the Manipal Health Enterprises IPO?
The IPO size is Rs 9,275 crore, comprising a fresh issue of 13.56 crore shares aggregating to Rs 8,000 crore and an OFS of 2.16 crore shares.
When is Manipal Health Enterprises IPO open and close for subscription?
Open for subscription from July 29, 2026 to July 31, 2026, with allotment on August 3, 2026 and listing on August 5, 2026.
What is the price band and upper price for the Manipal Health Enterprises IPO?
The price band is Rs 560-590 per share, with an upper price of Rs 590.
What is the expected listing price and listing gain?
Estimated listing price is Rs 615 per share, implying an estimated listing gain of about 4.24%.
What will the IPO proceeds be used for?
Proceeds will repay outstanding borrowings of its subsidiary, Manipal Hospitals Private Ltd.; acquire a minority stake in Sahyadri Hospitals Private Limited; and meet general corporate purposes.
What is the retail investment entry point for this IPO?
Retail investors must bid for at least one lot of 25 shares, with a lot size of 25; at the upper price, the minimum investment is Rs 14,750.
Conclusion
For the retail investor, the Manipal Health Enterprises IPO presents a blended proposition: a large healthcare platform seeking to fund growth and optimize leverage, paired with a pricing plan that hints at modest near-term upside, contingent on market demand. The combination of a Rs 9,275 crore offer, a Rs 560-590 price band, and an estimated listing price around Rs 615 suggests a potential listing gain near 4.24%, subject to market conditions. The proceeds structure emphasizes debt repayment for a subsidiary and minority stake acquisitions–signals of strategic intent that could compound the hospital network’s growth trajectory over time.
Open your trading and demat account here
Reference :
1 : Ndtvprofit
Reliance Infrastructure Share Price: July 27, 2026 Moves And What They Signal For Retail Investors
Key Takeaways
- The reliance infrastructure share price began July 27, 2026 at Rs 60.64, then dipped to an intraday low of Rs 60.04, after opening below the prior close of Rs 63.19.
- The stock has fallen 5% in one week, 22% in one month, 62% year-to-date, and 83% in the last year, highlighting ongoing downside risk for a small-cap name.
- Broader markets showed strength with the NSE Nifty 50 up 0.8% to 23,964.50 and the BSE Sensex up 0.8% to 76,696.38 on the same day.
- Regulatory headlines included SEBI rejecting Anil Ambani group settlements; ADAG stands for Anil Dhirubhai Ambani Group.
The reliance infrastructure share price began July 27, 2026 at Rs 60.64, below the previous close of Rs 63.19, and dipped to an intraday low of Rs 60.04–a move that compressed about 5% on the session. This sharp open against a rising market backdrop underscores how a single small-cap stock can diverge from broad indices and trigger risk questions for retail investors. As the day unfolded, the NSE Nifty 50 rose 0.8% to 23,964.50 and the BSE Sensex climbed 0.8% to 76,696.38, signaling that microcaps can ride different waves even when large caps advance.
The price action is part of a longer, well-documented downtrend. The reliance infrastructure share price has fallen 83% in the last one year and 62% year-to-date. The stock is described as a Small-Cap Stock Under Rs 100, which typically carries higher volatility and liquidity challenges relative to larger-caps. In context, Reliance Infrastructure is a major shareholder in Reliance Power, a relationship that investors monitor for spillover risk between infrastructure and energy assets.
Reliance Infrastructure Share Price On July 27, 2026: A Sharp Open And Decline
The stock opened at Rs 60.64 against a previous close of Rs 63.19 and then extended losses to drop about 5% on the day, hitting an intraday low of Rs 60.04. That intraday swing is a reminder of risk in microcap names, where liquidity and market perception can drive sharp reversals even when macro markets trend higher. reliance infrastructure share price dynamics like these are exactly what active and passive investors weigh when assessing exposure to small caps in India.
| Price Point | Value (Rs) |
|---|---|
| Open | 60.64 |
| Previous Close | 63.19 |
| Intraday Low | 60.04 |
Beyond the intraday move, the security’s longer-term trajectory has been punctuated by outsized declines. The 1 Week decline stands at -5%, 1 Month at -22%, Year To Date at -62%, and Last 1 Year at -83%. These figures underscore the risk-reward trade-off typical of small-cap stocks trading under Rs 100, where volatility can be dramatic and sustained directional moves are less predictable than in blue-chip counters.
| Time Frame | Decline |
|---|---|
| 1 Week | -5% |
| 1 Month | -22% |
| Year To Date | -62% |
| Last 1 Year | -83% |
Market Context: How Nifty 50 And Sensex Movements Relate To The Reliance Infrastructure Share Price
The day’s price action did not occur in isolation. The NSE Nifty 50 rose 0.8% to 23,964.50, while the BSE Sensex gained 0.8% or 637 points to 76,696.38. For a retail investor, this divergence between macro indices and microcap performance on the same day can be a critical reminder: broad market strength does not guarantee breadth of gains across smaller, more illiquid names. The interplay between macro sentiment and stock-level liquidity often defines whether a name like Reliance Infra stabilizes or slides further.
In the corporate tapestry, Reliance Infrastructure is a major shareholder in Reliance Power, a linkage investors watch for sectoral spillovers. Notably, in 2025, Reliance Infra had delivered multibagger returns on a three-year basis, illustrating that a stock can alternate between periods of strong outperformance and extended drawdowns. As a Small-Cap Stock Under Rs 100, the price action of this name continues to be a case study in the risk-reward calculus for retail investors who allocate to microcaps and thematic plays in infrastructure and energy.
For a deeper, data-driven read on price movements and to explore institutional-grade research on any stock, you can consult Swastika's Sarthi AI stock assistant.
Regulatory News And ADAG: SEBI's Rejection Of Anil Ambani Group Settlements
Adding a regulatory lens to the price action, SEBI had rejected applications by industrialist Anil Ambani and his corporate group to settle allegations of misusing company funds. The ADAG acronym stands for Anil Dhirubhai Ambani Group. This development matters for sentiment around the ADAG ecosystem and can influence risk appetite for stocks linked to or associated with the Ambani-led group. While regulatory headlines do not always translate into immediate price moves, they shape investor expectations, liquidity dynamics, and potential re-rating of risk in affected names.
Investment Takeaways For Retail Investors Battling A Small-Cap Stock Under Rs 100
From a practical standpoint, the current price action reinforces a few core takeaways for retail investors. First, liquidity in stocks described as small-cap stocks under Rs 100 tends to be episodic; second, price resilience often hinges on earnings visibility, project execution, and credit access; and third, diversification across sectors reduces single-name risk in a volatile space. The 2025 performance, where Reliance Infra had delivered multibagger returns on a three-year basis, shows that a stock can alternate between rapid gains and sharp declines over multi-year windows. These dynamics underscore the importance of a structured risk management framework, disciplined position sizing, and a readiness to adapt to regulatory or market shocks.
For readers who want a structured, AI-assisted overview, Swastika's Sarthi AI stock assistant can help uncover deeper insights across this and similar names: Swastika's Sarthi AI stock assistant.
Frequently Asked Questions
What happened to the Reliance Infrastructure share price on July 27, 2026?
The stock opened at Rs 60.64 against a previous close of Rs 63.19 and extended losses to an intraday low of Rs 60.04, marking a roughly 5% drop on the session.
How did Reliance Infrastructure stock perform over the last year and year-to-date?
The stock is down 83% in the last one year and down 62% year-to-date.
What is the market capitalization mentioned for Reliance Infrastructure on the date reported?
The market cap is reported as Rs 2,521.25 crore.
What does the acronym ADAG stand for in relation to Anil Ambani Group?
ADAG stands for Anil Dhirubhai Ambani Group.
What resource can retail investors use for deeper stock analysis mentioned in the article?
Retail investors can use Swastika's Sarthi AI stock assistant at the following link: https://www.swastika.co.in/sarthi.
Conclusion
What the July 27 price action teaches retail investors is that a small-cap stock in a high-visibility group can experience outsized swings even when major indices trend higher. The reliance infrastructure share price narrative on that day sits at the intersection of market breadth, liquidity risk, and regulatory headlines–the kind of combination that tests portfolio risk controls and investment discipline.
Open your trading and demat account here
Reference :
1 : Ndtvprofit
Tanishq Gold Price Today: What Retail Investors Should Know About 22K Rates Across Brands
Key Takeaways
- tanishq gold price today shows Rs 13,275 per gram for 22K across major cities as of July 24, 2026.
- On July 23, 2026, Tanishq quoted Rs 13,445 per gram, Malabar Gold & Diamonds and Joyalukkas Rs 13,500, and Kalyan Jewellers Rs 13,400.
- IBJA rates show 22 KT gold around Rs 13,933 per gram (AM) and Rs 14,113 per gram (PM).
- GST and making charges apply; Swastika's Sarthi AI stock assistant can help you decide the best moment to buy.
In a market where a single gram of gold can swing by tens of rupees in a day, retail investors want to know one thing: tanishq gold price today, and how that price stacks up across the brands they trust. The 22K rate across major Indian jewellers is not just a number; it reflects brand policies on making charges, raw metal costs, and local demand. This guide pulls from the latest price lists on brand websites and official IBJA indicators to give you a clear, practical view of the 22K gold landscape as of late July 2026.
Understanding tanishq gold price today helps you compare the direct per-gram price you would pay at a showroom. While the absolute numbers move with market moods, the relative differences across brands often reflect factors such as discounts, making charges, and brand position. The following data is drawn from brand price lists and IBJA indicators as of July 24, 2026, and is exclusive of GST and making charges.
Tanishq Gold Price Today Across Major Indian Cities: A City-Wise Snapshot
Across major cities (New Delhi, Mumbai, Chennai, Kolkata, Thiruvananthapuram, Coimbatore and Bengaluru), the 22K price at Tanishq is Rs 13,275 per gram as of July 24, 2026. The July 23, 2026 price across the same cities was Rs 13,445 per gram, indicating a slight daily softening in the brand's 22K rate. Keep in mind that these figures are exclusive of 3% GST and making charges, which jewellery retailers apply to the final purchase price. This city-wise snapshot helps you compare the 22K rate you would encounter at a local showroom and decide whether to buy now or wait for a dip.
22K Gold Price Across Brands On July 23-24, 2026: Brand-Wise Price Table
| Brand | July 24, 2026 (AM) | July 23, 2026 (PM) | Notes |
|---|---|---|---|
| Tanishq | Rs 13,275 | Rs 13,445 | As of 11:39 AM on Jul 24; 23 Jul PM data |
| Malabar Gold & Diamonds | Rs 13,230 | Rs 13,500 | As of 11:39 AM on Jul 24; 23 Jul PM data |
| Joyalukkas | Rs 13,230 | Rs 13,500 | As of 11:39 AM on Jul 24; 23 Jul PM data |
| Kalyan Jewellers | Not Updated | Rs 13,400 | July 23 2026 4 PM; July 24 update pending |
Note: All rates exclude 3% GST and making charges.
Ibja Rates And Retail Gold Price Today: How Official Rates Align With Market Prices
IBJA's indicative retail selling rates provide an official baseline that market quotes can exceed or dip below, depending on brand margins and local demand. As of July 24, 2026 (am rates), Fine Gold (999) is Rs 14,276 per gram; 22 KT Gold Rs 13,933 per gram; 20 KT Gold Rs 12,705 per gram; 18 KT Gold Rs 11,563 per gram; 14 KT Gold Rs 9,208 per gram; Silver (999) Rs 2,19,556 per kilogram.
For July 23, 2026 (pm rates), the IBJA snapshot showed: Fine Gold (999) Rs 14,461 per gram; 22 KT Gold Rs 14,113 per gram; 20 KT Gold Rs 12,870 per gram; 18 KT Gold Rs 11,713 per gram; 14 KT Gold Rs 9,327 per gram; Silver Rs 2,22,480 per kilogram.
These official rates give you a baseline against which brand quotes are measured, and the final cash-purchase price remains subject to GST and making charges that vary by jeweller and location. For deeper market interpretation and stock-level considerations, you can refer to Swastika's Sarthi AI stock assistant.
According to Prithviraj Kothari of RiddiSiddhi Bullions Ltd., Gold and Silver fell this week as rising oil prices, fueled by escalating Middle East tensions, boosted expectations of tighter US monetary policy. Trump's warnings against Iran pushed Brent crude past 100 dollars a barrel, while new US tariffs on nearly 60 countries–including India–further dampened sentiment. Markets now await next week's Fed meeting, where rates are expected to stay unchanged, though an 81% chance of a September hike is being priced in. Technically, Gold's key support and resistance levels sit near 4,000 and 4,200, while Silver's crucial zones are 55 and 63, determining the metals' next major moves.
Reference :
1 : Economictimes
Gold Outlook And Market Signals For Retail Investors
What do these numbers mean for the average retail investor? The movement in brand quotes over a short span often reflects a mix of raw metal cost, the jewellery brand's margins, and the broader macro environment. The quote from the gold outlook suggests a confluence of external factors–oil prices, global monetary policy expectations, and trade actions–that can nerve-wracking in the short term, but may stabilise as markets digest new data. Technically, gold's important support and resistance levels sit near the $4,000 and $4,200 marks, and silver's critical zones are near $55 and $63 per ounce, which helps anchor short-term trading and long-term financial planning.
From a practical standpoint, retail investors should frame their buying decisions around two ideas: first, understand the per-gram price you face at the jeweller, i.e., the base price across brands; second, always add GST and making charges to convert the base price into the final cash outlay. The data also underscores that while 24K (pure) gold tends to fetch a higher price per gram than 22K, the difference isn't only about purity–it's about the additional charges and jewellery design quotes that accompany each piece. If you are contemplating a purchase, consider a price alert across your preferred jewellers and a plan for a 'dip buy' if the price touches a level near the IBJA baseline or the mid-range of the brand quotes. For deeper, data-driven insights on gold and other asset classes, consult Swastika's Sarthi AI stock assistant.
Related Reads
Frequently Asked Questions
What is the current tanishq gold price today for 22K gold across major cities?
As of July 24, 2026, the 22K gold price across major Indian cities shows Tanishq at Rs 13,275 per gram, Malabar Gold & Diamonds at Rs 13,230 per gram, Joyalukkas at Rs 13,230 per gram, and Kalyan Jewellers at Rs 13,400 per gram (4 PM data for July 23, 2026; July 24 data not yet updated). These quotes exclude 3% GST and making charges. The IBJA 22KT rate is Rs 13,933 per gram (AM, July 24, 2026) and Rs 14,113 per gram (PM, July 23, 2026).
Which brand shows the lowest 22K price today among the brands listed?
As of 24 July 2026, Malabar Gold & Diamonds and Joyalukkas both quote Rs 13,230 per gram for 22K, which is the lowest among the listed brands. Tanishq is Rs 13,275 per gram, while Kalyan Jewellers is Rs 13,400 per gram (4 PM, 23 July 2026).
What are IBJA rates for 22KT gold today?
The IBJA 22 KT gold rate on 24 July 2026 (AM) is Rs 13,933 per gram; on 23 July 2026 (PM) it was Rs 14,113 per gram. Other indicators include 999 Fine Gold Rs 14,276 per gram (AM 24 Jul 2026); 20KT Rs 12,705; 18KT Rs 11,563; 14KT Rs 9,208; Silver 999 Rs 2,19,556 per kilogram (AM 24 Jul 2026) and Rs 2,22,480 per kilogram (PM 23 Jul 2026).
Are these rates inclusive of GST and making charges?
No. All the listed base prices are exclusive of 3% GST and making charges. The final outlay depends on the jewellery's weight, design, and the retailer's margins.
Where can I get deeper insights or real-time analysis on gold prices and stock data?
For deeper market insights and stock-level analysis, use Swastika's Sarthi AI stock assistant:Swastika's Sarthi AI stock assistant.
Conclusion
In practical terms for a retail investor right now, the most important takeaway is to treat the 22K gold price today data as a guide rather than a single price. The brand quotes show modest variation–Malabar Gold & Diamonds and Joyalukkas at Rs 13,230 per gram, Tanishq at Rs 13,275 per gram, and Kalyan Jewellers at Rs 13,400 (with July 24 data pending)–and the IBJA baseline helps you calibrate whether a current retail quote is fair. Remember that GST and making charges will apply to the final purchase price; the exact outlay depends on the piece's weight and design. A practical next step is to build a price watchlist across your preferred brands, set triggers for dips near the IBJA baseline, and use Swastika's Sarthi AI stock assistant to align gold decisions with your broader investment plan.
As always, the market for gold remains a balance of physical demand, macroeconomic forces, and brand strategies. By staying informed, you can time purchases more confidently, optimize value, and maintain a disciplined approach to jewellery buying or gold investment.
Big Budget
Popular Articles
.avif)
.avif)
.avif)
START YOUR INVESTMENT JOURNEY
Get personalized advice from our experts
- Dedicated RM Support
- Smooth and Fast Trading App
